3,032 results match your criteria Squamous Cell Carcinoma of the Urinary Bladder

Clinical Characteristics of Urinary Bladder Cancer in the Sudan; Evidence of Pathoetiology Changes.

Gulf J Oncolog 2022 May;1(39):16-20

Department of Surgery, Assafa College, Khartoum, Sudan.

Introduction: Bladder cancer (BC) is highly heterogeneous with regard to clinical course, etiology, histology, and geographic distribution. Recent clinical observations suggest changes in the pattern of BC in the Sudan perhaps due to lifestyle change following the massive displacement from rural to urban areas. The present study aimed to characterize the clinical profile of the BC among Sudanese patients and compare it with what has been previous reported. Read More

View Article and Full-Text PDF

Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.

Cells 2022 May 31;11(11). Epub 2022 May 31.

Medical Laboratory CSD, 03022 Kyiv, Ukraine.

In this study, we investigated the relationship between the tumor immune microenvironment (TIME), histological differentiation and hypoxia in patients with muscular-invasive urothelial carcinomas (MIUC) after radical cystectomy. Forty-two cases of pT2-3N0M0 MIUCs underwent clinical, histological and immunohistochemical evaluation by counting CD8+, FOXP3+, CD68+, CD163+ cells and polymorphonuclear leukocytes (PMN) in intra-tumoral and peritumoral areas, assessing PD-L1 and GLUT1 expression for defining the impact of tumor immune contexture on patients' outcomes. Five-year survival rates and overall survival were calculated. Read More

View Article and Full-Text PDF

Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy.

Int J Radiat Oncol Biol Phys 2022 May 16. Epub 2022 May 16.

Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology. Electronic address:

Purpose: Definitive radiation therapy with concurrent chemotherapy is curative for nonmetastatic squamous cell carcinoma of the anus (SCCA). However, the true effect of chemoradiation on long-term functional outcomes is poorly understood owing to limited follow-up and patient-reported outcomes (PROs).

Methods And Materials: We conducted a cross-sectional survey of 248 patients with SCCA treated with definitive intensity modulated radiation and concurrent chemotherapy from 2010 to 2018 who were alive and without recurrence. Read More

View Article and Full-Text PDF

A surgical case of high-grade urothelial carcinoma of the renal pelvis complicated with giant hydronephrosis, giving rise to diagnostic difficulties on a cytological examination.

Diagn Pathol 2022 May 11;17(1):47. Epub 2022 May 11.

Kanazawa Medical University Hospital, 1-1, Ishikawa, 920-0293, Uchinada, Japan.

Background: We report a surgical case of urothelial carcinoma of the renal pelvis, resulting in diagnostic difficulties on cytological examination.

Case Presentation: A man in his late 70s underwent nephrectomy for giant hydronephrosis and renal cysts after nephrostomy and renal cyst puncture and drainage. On all cytological examinations performed before surgery, including nephrostomy urine, renal cyst fluid, catheterized bladder urine, and bladder washings, we were unable to make any conclusive diagnosis of malignancy. Read More

View Article and Full-Text PDF

Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.

Appl Immunohistochem Mol Morphol 2022 May-Jun 01;30(5):326-332. Epub 2022 Mar 22.

NordiQC, Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark.

Immunohistochemistry for Uroplakin (UP) II and III is used to determine urothelial origin of carcinomas of unknown primary site and are especially valuable to differentiate urothelial carcinomas (UCs) from lung squamous cell carcinomas and prostate carcinomas. In the Nordic immunohistochemical Quality Control assessment scheme, only 45% of the participants obtained a sufficient staining result for UP. Primary antibodies (Abs) against UPII were most successful with a pass rate of 86%. Read More

View Article and Full-Text PDF

Histopathologic findings in patients who have undergone blue light cystoscopy and bladder biopsy or transurethral resection: A contemporary clinicopathologic analysis of 100 cases.

Pathol Res Pract 2022 Jun 26;234:153916. Epub 2022 Apr 26.

Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Pathology, Veterans Affairs Medical Center, Decatur, GA 30033, USA. Electronic address:

Blue light cystoscopy is utilized to assist Urologists highlight potentially malignant -bladder lesions that might otherwise be undetected by standard cystoscopic techniques. There is a paucity of published studies in the literature regarding the histopathologic findings in this setting, especially regarding false positive lesions. A search was performed for patients who underwent blue light cystoscopy at our institution from 2017 to 2021. Read More

View Article and Full-Text PDF

Use of immunotherapy in clinical management of genitourinary cancers - a review.

Cancer Treat Res Commun 2022 17;31:100564. Epub 2022 Apr 17.

University of California Irvine, Division of Hematology/Oncology, USA.

Checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have revolutionized oncologic care delivery, including clinical management of genitourinary malignancies. Despite significant associated improvement in patient outcomes, molecular heterogeneity of tumors, variable tumor engagement with the immune response, and unique patient factors likely account for different clinical responses to immunotherapy agents. A search for predictive biomarkers of treatment response to checkpoint inhibitors is underway and several candidates, although imperfect, have been identified. Read More

View Article and Full-Text PDF

Coincidental finding of a giant bladder calculus and squamous cell carcinoma of bladder: A case report.

SAGE Open Med Case Rep 2022 14;10:2050313X221091411. Epub 2022 Apr 14.

Department of Obstetrics and Gynecology, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.

Chronic irritation of bladder by urinary bladder calculus is a known risk factor for bladder cancer. The use of Wrigley's obstetrical forceps in general surgical practice is a rare event. Herein, we report a case of a giant urinary bladder calculus which was removed by Wrigley's obstetrical forceps during open cystolithotomy. Read More

View Article and Full-Text PDF

Squamous cell papilloma a rare urinary bladder tumor, case report and operative video.

Urol Case Rep 2022 Jul 4;43:102074. Epub 2022 Apr 4.

Department of Urology, Hamad Medical Corporation, Doha, Qatar.

Bladder noninvasive squamous lesions are usually rare; here, we are presenting a case of 39 years old male patient with a benign squamous cell papilloma. The tumor grossly presented as cauliflower mass mimicking squamous cell carcinoma, while histologically, the tumor showed extensive keratinization at its surface and showed no nuclear atypia or stromal invasion. This tumor is benign and extremely rare. Read More

View Article and Full-Text PDF

Intestinal metastasis from carcinoma cervix: An (un) common occurrence in a common cancer. A series of five cases from a single institution.

Indian J Pathol Microbiol 2022 Apr-Jun;65(2):396-400

Department of Pathology, Tata Main Hospital, Jamshedpur, Jharkhand, India.

Carcinoma cervix usually spreads directly to contiguous structures, such as the vagina, urinary bladder, ureter, and rectum. Intestinal metastasis from cervical cancer is very uncommon and accounts for less than 4% of cases and to date, 24 cases have been reported in Medical literature. These may be asymptomatic or present with features of intestinal obstruction, bowel wall perforation, and mimic acute abdomen. Read More

View Article and Full-Text PDF

Bone ın bladder.

J Nephrol 2022 04 6;35(3):1043-1044. Epub 2022 Apr 6.

Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.

View Article and Full-Text PDF

Barrier-Forming Potential of Epithelial Cells from the Exstrophic Bladder.

Am J Pathol 2022 Jun 28;192(6):943-955. Epub 2022 Mar 28.

Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, York, United Kingdom. Electronic address:

Bladder exstrophy (BEX) is a rare developmental abnormality resulting in an open, exposed bladder plate. Although normal bladder urothelium is a mitotically quiescent barrier epithelium, histologic studies of BEX epithelia report squamous and proliferative changes that can persist beyond surgical closure. The current study examined whether patient-derived BEX epithelial cells in vitro were capable of generating a barrier-forming epithelium under permissive conditions. Read More

View Article and Full-Text PDF

Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.

Urol Oncol 2022 06 27;40(6):275.e1-275.e10. Epub 2022 Mar 27.

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX; Urology and Nephrology Center, Mansoura University, Dakahlia Governorate, Egypt. Electronic address:

Background: To compare the overall survival (OS) outcomes of non-muscle invasive bladder cancer (NMIBC) patients with variant histology who underwent radical cystectomy (RC) vs. bladder preservation therapy (BPT).

Methods: We investigated the National Cancer Database for NMIBC patients with variant histological features. Read More

View Article and Full-Text PDF

Squamous Cell Carcinoma of the Sigmoid Colon: A Path Less Traveled.

Cureus 2022 Feb 16;14(2):e22297. Epub 2022 Feb 16.

Surgical Gastroenterology, All India Institute of Medical Sciences, Rishikesh, IND.

Squamous cell carcinoma (SCC) involving the gastrointestinal tract is exceptionally rare, except in the esophagus and the anal canal. In the hindgut, a common site of involvement is the colo-rectum, commonly seen in the fifth decade of life. The presentation is usually in the advanced stages and carries a poor prognosis. Read More

View Article and Full-Text PDF
February 2022

A Curious Case of Hypercalcemia.

R I Med J (2013) 2022 Apr 1;105(3):39-41. Epub 2022 Apr 1.

Department of Internal Medicine, Kent Hospital, Warwick, RI.

Humoral hypercalcemia of malignancy is rarely seen in urothelial cancer. In this report, we present a case of an 81-year-old female patient who presented with a markedly elevated calcium level leading to severe altered mental status and was found to have urothelial cancer. To our knowledge, only three cases of urothelial carcinoma with squamous cell differentiation have been reported. Read More

View Article and Full-Text PDF

The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.

Oxid Med Cell Longev 2022 11;2022:8297011. Epub 2022 Mar 11.

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Purpose: This study is aimed at systematically analyzing the expression, function, and prognostic value of six transmembrane epithelial antigen of the prostate 1 (STEAP1) in various cancers.

Methods: The expressions of STEAP1 between normal and tumor tissues were analyzed using TCGA and GTEx. Clinicopathologic data was collected from GEPIA and TCGA. Read More

View Article and Full-Text PDF

Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Curr Treat Options Oncol 2022 04 21;23(4):578-593. Epub 2022 Mar 21.

Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Opinion Statement: Nectin-4 is a tumor-associated antigen that is highly expressed on various cancer cells, and it has been further proposed to have roles in tumor development and propagation ranging from cellular proliferation to motility and invasion. Nectin-4 blockade reduces tumor proliferation and induces apoptosis in several malignancies. Nectin-4 has been used as a potential target in antibody-drug conjugate (ADC) development. Read More

View Article and Full-Text PDF

Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.

J Pathol Clin Res 2022 05 14;8(3):279-293. Epub 2022 Mar 14.

Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.

Pure squamous cell carcinoma (SCC) is the most common pure variant form of bladder cancer, found in 2-5% of cases. It often presents late and is unresponsive to cisplatin-based chemotherapy. The molecular features of these tumours have not been elucidated in detail. Read More

View Article and Full-Text PDF

Penile extramammary Paget disease associated with urothelial carcinoma in situ: Case report and literature review.

J Cutan Pathol 2022 Jul 23;49(7):663-668. Epub 2022 Mar 23.

Laboratory Medicine Program, University Health Network and Princess Margaret Cancer Center, Toronto, Ontario, Canada.

Background: Extramammary Paget disease (EMPD) is an uncommon disease affecting older men and women. Clinically, it appears as a plaque lesion with an erythematous or leukoplakic background in regions with abundant apocrine glands such as female external genitalia, perineum, scrotum, and penis.

Methods: We are presenting an 85-year-old patient with recurrent erythematous plaque lesions involving the penis and known to have urothelial carcinoma (UC) in situ of the bladder. Read More

View Article and Full-Text PDF

Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.

Int J Environ Res Public Health 2022 03 4;19(5). Epub 2022 Mar 4.

Malaysian National Cancer Registry Department, National Cancer Institute, Ministry of Health Malaysia, Putrajaya 62250, Selangor, Malaysia.

Background: Malaysia has the third highest crude mortality rates of bladder cancer within Southeast Asia. We aimed to identify the prognostic factors for bladder cancer patients in Malaysia.

Methods: A retrospective population-based study was conducted among patients diagnosed between 2007 and 2011. Read More

View Article and Full-Text PDF

Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.

World J Urol 2022 May 26;40(5):1167-1174. Epub 2022 Feb 26.

Department of Urology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain.

Purpose: To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette-Guérin (BCG) immunotherapy for T1 squamous bladder cancer (BCa).

Methods: We retrospectively analysed 188 T1 high-grade squamous BCa patients treated between 1998 and 2019 at fifteen tertiary referral centres. Median follow-up time was 36 months (interquartile range: 19-76). Read More

View Article and Full-Text PDF

Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?

Urol Oncol 2022 06 23;40(6):273.e11-273.e20. Epub 2022 Feb 23.

Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy.

Objective: To compare the accuracy in detecting variant histologies (VH) at transurethral resection of bladder (TURB) and radical cystectomy (RC) specimen among tertiary referral centres, in order to investigate potential reasons of discrepancies from the pathological point of view.

Patients And Methods: Clinical and histopathological data of TURB specimen and subsequent cystectomy specimen of 3,445 RC candidate patients have been retrospectively collected from 24 tertiary referral centres between 1980 and 2021. VH considered in the analysis were pure squamous cell carcinoma, urothelial carcinoma with squamous differentiation, pure adenocarcinoma, urothelial carcinoma with glandular differentiation, micropapillary bladder cancer (BCa), neuroendocrine BCa, and other variants. Read More

View Article and Full-Text PDF

Yolk sac differentiation in urothelial carcinoma - A rare variant originating from aberrant differentiation of sarcomatoid components.

Ann Diagn Pathol 2022 Jun 12;58:151923. Epub 2022 Feb 12.

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Yolk sac differentiation occurs in somatic neoplasms of the gastrointestinal and gynecologic tracts; it has rarely been reported in urothelial carcinoma. Here, we report three cases of yolk sac differentiation in sarcomatoid urothelial carcinoma. The epithelioid component of the sarcomatoid urothelial carcinoma showed divergent differentiation, including squamous, conventional glandular, small cell carcinoma, and yolk sac components. Read More

View Article and Full-Text PDF

Carcinosarcoma is an aggressive subtype of bladder cancer: A population-based study.

Cancer Med 2022 Jun 18;11(11):2216-2223. Epub 2022 Feb 18.

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

Background: Case reports of bladder carcinosarcoma (BCS) indicate high rates of recurrence and metastasis and poor prognosis. However, the differences in clinicopathologic characteristics and prognosis between BCS and conventional bladder cancer histologies (transitional cell carcinoma [TCC], squamous cell carcinoma [SCC] and adenocarcinoma [AC]) have not been fully clarified in a large study. Therefore, we conducted a large population-based study to further investigate these differences. Read More

View Article and Full-Text PDF

Urinary bladder Schistosoma haematobium-related squamous cell carcinoma: a report of two fatal cases and literature review.

Trop Dis Travel Med Vaccines 2022 Feb 15;8(1). Epub 2022 Feb 15.

Faculty of Health Sciences, Abdou Moumouni University, Niamey, Niger.

Background: Schistosomiasis is still a public health issue in certain areas of developing countries (especially in sub-saharan Africa). Schistosoma haematobium is a proven carcinogenic agent that causes mainly bladder squamous cell carcinoma. This type of cancer has characteristic epidemiological, clinical and histopathological features with poor prognosis as compared to other urinary bladder cancers not associated with this parasite. Read More

View Article and Full-Text PDF
February 2022

A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.

World J Urol 2022 Feb 9. Epub 2022 Feb 9.

Sorbonne University, GRC5 Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Paris, France.

Purpose: To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC).

Methods: Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections. Read More

View Article and Full-Text PDF
February 2022

T1 bladder carcinoma with variant histology: pathological features and clinical significance.

Virchows Arch 2022 May 4;480(5):989-998. Epub 2022 Feb 4.

Departments of Pathology and Laboratory Medicine and Urology, School of Medicine, Indiana University, Indianapolis, IN, USA.

The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Read More

View Article and Full-Text PDF

Primary urethral carcinoma: Results from a single center experience.

Actas Urol Esp (Engl Ed) 2022 Mar 2;46(2):70-77. Epub 2022 Feb 2.

Departamento de Urología, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.

Introduction And Aim Of The Study: Primary urethral carcinoma (PUC) is a rare neoplastic disease arising in the urethra, without any evidence of a previous or synchronous carcinoma of the entire urinary tract. Since rare diseases are often incorrectly diagnosed and managed, the aim of this study was to analyze the experience of a single urology center in the treatment of PUC, focusing on neoplasms arising from the male anterior urethra.

Materials And Methods: Medical records of patients with neoplasms at the level of the penile and bulbar urethra who presented at our tertiary referral center between January 1988 and December 2018 were retrospectively reviewed. Read More

View Article and Full-Text PDF

Bladder cancer in Saudi Arabia: a registry-based nationwide descriptive epidemiological and survival analysis.

Ann Saudi Med 2022 Jan-Feb;42(1):17-28. Epub 2022 Feb 3.

From the College of Medicine, King Saud bin Abdulaziz University for Health Sciences.

Background: Our understanding of the risk factors, prevalence, incidence rate, and age distribution of bladder cancer (BC) in Saudi Arabia is insufficient due to limited data.

Objective: Describe the epidemiology and analyze factors associated with survival in patients with BC in Saudi Arabia.

Design: Retrospective medical record review. Read More

View Article and Full-Text PDF
February 2022